BioCentury
ARTICLE | Financial News

Apexigen announces $73M in series B, C rounds

August 8, 2018 5:49 PM UTC

Immuno-oncology company Apexigen Inc. (San Carlos, Calif.) raised a total of $73 million in its series B and C rounds. The company closed its series B round with $15 million led by Decheng Capital, while the $58 million series C round was led by 3E Bioventures Capital, Virtus Inspire Ventures and SV Tech Ventures.

Apexigen's lead candidate APX005M is in Phase II testing to treat melanoma, non-small cell lung cancer (NSCLC), pancreatic cancer and renal cell carcinoma (RCC). The candidate is a humanized mAb that targets CD40...

BCIQ Company Profiles

Apexigen Inc.

BCIQ Target Profiles

CD40